Simultaneous combined transplantation: Intricacies in immunosuppression management.

Simultaneous combined transplantation (SCT), i.e. the transplantation of two solid organs within the same procedure, can be required when the patients develop more than one end-stage organ failure.

Identification of the novel HLA-DQA1*02:32 allele by next-generation sequencing.

HLA-DQA1*02:32 differs from DQA1*02:01:01 by one nucleotide substitution in codon 210 in exon 4.

Utility of Routine Post Kidney Transplant Anti-HLA Antibody Screening.

Introduction: donor-specific antibody (dnDSA) is a strong biomarker associated with the development of antibody-mediated rejection (AMR) and graft loss after kidney transplantation. This procedure is expensive; however, systematic annual screening was recommended by some national organ transplant agencies or societies even though its clinical utility was not clearly established.

Methods: To address this question, we retrospectively assessed the incidence of dnDSA according to the test justification (clinically indicated or systematic) in a cohort of low-immunological risk patients, defined by being nonhuman leukocyte antigen (non-HLA)-sensitized and having no previous kidney transplants.

Identification of the novel HLA-DRB1*14:253 allele by next-generation sequencing.

HLA-DRB1*14:253 differs from DRB1*14:54:01 by one nucleotide substitution in codon 233 in exon 5.

Identification of the novel HLA-DQB1*03:512 allele by next-generation sequencing.

HLA-DQB1*03:512 differs from DQB1*03:02:01 by one nucleotide substitution in codon 89 in exon 2.

Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report.

Bacterial recombinant cysteine protease Ides (imlifidase, Idefirix®, Hansa Biopharma) is used to prevent humoral transplant rejection in highly HLA-sensitized recipients, and to control IgG-mediated autoimmune diseases. We report the case of a 51 years old woman suffering from lupus nephritis with end stage kidney disease, grafted for the second time and pre-treated with imlifidase. The patient was HLA-hypersensitized (calculated Panel Reactive Antibodies [Abs], cPRA>99 %) and has three preformed Donor Specific Antibodies (DSA).

Identification of liver transplant biopsy phenotypes associated with distinct liver biological markers and allograft survival.

The intricate association between histologic lesions and circulating antihuman leucocyte antigen donor-specific antibodies (DSA) in liver transplantation (LT) requires further clarification. We conducted a probabilistic, unsupervised approach in a comprehensively well-annotated LT cohort to identify clinically relevant archetypes. We evaluated 490 pairs of LT biopsies with DSA testing from 325 recipients transplanted between 2010 and 2020 across 3 French centers and an external cohort of 202 biopsies from 128 recipients.

Characterization of the novel HLA-DRB3*02:193 allele by sequencing-based typing.

HLA-DRB3*02:193 differs from DRB3*02:02:01:11 by one nucleotide substitution in exon 1, and intronic changes.

Accuracy of Serological Screening for the Diagnosis of Celiac Disease in Type 1 Diabetes Children.

: Patients with type 1 diabetes (T1D) are considered at high-risk for developing celiac disease (CD). The purpose of our study was to determine the prevalence of CD among children who were followed in our unit for T1D using the latest ESPGHAN guidelines, and avoiding intestinal biopsies in some of the children. Materials and : We performed a prospective monocentric study, which included 663 T1D children between June 2014 and June 2016.

Identification of the novel HLA-C*03:632 allele by next-generation sequencing.

HLA-C*03:632 differs from C*03:03 by one nucleotide substitution in codon 285 in exon 5.

Progression of histological lesions after ABO incompatible kidney transplantation.

Recent large meta-analyses suggested a poorer long-term patients' and grafts' outcomes after ABO incompatible (ABOi) living-donor kidney transplantation (LDKT) compared to ABO compatible LDKT. However, little is known about the long-term histological pattern after ABOi LDKT. We compared the histological features observed on protocol biopsies from 03/11 to 11/19 in 94 ABOi LDKT (including 14 with preformed Donor Specific Antibodies, pDSAs), 27 LDKT ABO compatible (ABOc) with pDSAs, and 21 ABOc without pDSAs) during the first five years post transplantation.

The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation.

During organ transplantation, ischemia/reperfusion injury and pre-formed anti-HLA antibodies are the main cause of delayed graft function and recovery through the activation of the complement system. By supplying oxygen during transplantation, M101 is suspected to avoid complement activation, however, a direct effect exerted by M101 on this pathway is unknown. This was tested by using functional assays (lymphocytotoxic crossmatch test, C3d Luminex-based assay, 50% complement hemolysis [CH50], and 50% alternative complement pathway [AP50/AH50]), and quantitative assays (C3, C3a, C4, C5, C5a, C6, C7, C8, C9 and sC5b-9).

Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases.

Disease modifying therapies compromise immune response to SARS-Cov2 or its vaccine in patients with immune system diseases (ISD). Therefore, analysis of the humoral and cellular responses against Spike is of utmost importance to manage ISD patients. A single-center retrospective study was conducted to evaluate the impact of COVID-19 immunization in 87 ISD patients and 81 healthy controls.

Monocytes are the main source of STING-mediated IFN-α production.

Background: Type I interferon (IFN-I) production by plasmacytoid dendritic cells (pDCs) occurs during viral infection, in response to Toll-like receptor 7 (TLR7) stimulation and is more vigorous in females than in males. Whether this sex bias persists in ageing people is currently unknown. In this study, we investigated the effect of sex and aging on IFN-α production induced by PRR agonist ligands.

The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation.

The identity of histocompatibility loci, besides human leukocyte antigen (HLA), remains elusive. The major histocompatibility complex (MHC) class I MICA gene is a candidate histocompatibility locus. Here, we investigate its role in a French multicenter cohort of 1,356 kidney transplants.

Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.

Background & Aims: Low calcineurin inhibitor (CNI) levels expose liver transplant recipients to rejection episodes and potentially to antibody-mediated rejection. There are little data on the impact of CNI-free immunosuppression on de novo donor-specific HLA antibody (dnDSA) development. Here we evaluated the prevalence of dnDSA in liver transplant recipients on CNI-free maintenance regimens and their associations with histopathological abnormalities of allografts.

Identification of the novel HLA-DQB1*03:471 allele by next-generation sequencing.

HLA-DQB1*03:471 differs from DQB1*03:02:01 by one nucleotide substitution in codon 142 in exon 3.

Identification of the novel HLA-DQA1*01:82 allele by next-generation sequencing.

HLA-DQA1*01:82 differs from DQA1*01:03:01 by one nucleotide substitution in codon 49 in exon 2.

Identification of the novel HLA-DRB1*04:335 allele by next-generation sequencing.

HLA-DRB1*04:335 differs from DRB1*04:01:01 by one nucleotide substitution in codon 28 in exon 2.

Identification of the novel HLA-DRB3*02:174 allele by next-generation sequencing.

HLA-DRB3*02:174 differs from DRB3*02:02:01 by one nucleotide substitution in codon 95 in exon 3.

Identification of the novel HLA-DQB1*06:386 allele by next-generation sequencing.

HLA-DQB1*06:386 differs from DQB1*06:46 by one nucleotide substitution in Codon 130 in Exon 3.

Identification of the novel HLA-DQB1*05:275 allele by next-generation sequencing.

HLA-DQB1*05:275 differs from DQB1*05:01 by one nucleotide substitution in codon 224 in exon 4.

Identification of the novel HLA-DPA1*01:49 allele by next-generation sequencing.

HLA-DPA1*01:49 differs from DPA1*01:03:01:04 by one nucleotide substitution in codon 119 in exon 3.